Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
Journal of Clinical Oncology2019Vol. 37(16), pp. 1412–1423
Citations Over TimeTop 1% of 2019 papers
Klaus‐Peter Dieckmann, Arlo Radtke, Lajos Géczi, Cord Matthies, Petra Anheuser, Ulrike Eckardt, Jörg Sommer, Friedemann Zengerling, Emanuela Trenti, Renate Pichler, Hanjo Belz, Stefan Zastrow, Alexander Winter, Sebastian Melchior, Johannes Hammel, Jennifer Kranz, Marius Bolten, S. Krege, Björn Haben, Wolfgang Loidl, Christian Ruf, Julia Heinzelbecker, Axel Heidenreich, Jann Frederik Cremers, Christoph Oing, Thomas Hermanns, Christian D. Fankhauser, Silke Gillessen, Hermann Reichegger, Richard Cathomas, Martin Pichler, Marcus Hentrich, Klaus Eredics, Anja Lorch, Christian Wülfing, Sven Peine, Werner Wosniok, Carsten Bokemeyer, Gazanfer Belge
Abstract
The M371 test outperforms the classic markers of GCT with both a sensitivity and a specificity greater than 90%. All histologic subgroups, except teratoma, express this marker. The test could be considered for clinical implementation after further validation.
Related Papers
- → Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses(2022)10 cited
- → Bilateral Malignant Testicular Germ Cell Cancer(1986)33 cited
- → Recurrent Seminoma with Sonographic and Pathologic Correlation(1992)
- [Retroperitoneal lymph node recurrence of seminoma 6 years after high orchiectomy].(2005)
- → PET imaging of testicular cancer(2022)